BLAFAR LIMITED

Their core work

Blafar is a Dublin-based SME operating in the biomedical materials and tissue engineering space. Their project portfolio indicates expertise in biopolymer development, cell culture technologies, and drug delivery systems, with applications spanning antibacterial medical materials, cancer therapeutics, and ophthalmology. As a participant in multiple Marie Skłodowska-Curie training networks, Blafar serves as an industry host for early-stage researchers, contributing commercial perspective and applied know-how to academic-led consortia. Their work sits at the intersection of biomaterials science and pharmaceutical applications.

What they specialise in

How they've shifted over time

All three of Blafar's H2020 projects started within a narrow 2015–2017 window, making it difficult to identify a clear directional shift. Their earliest work (HyMedPoly, MATRIXASSAY) focused on biomaterials and cell assay platforms, while their most recent project (3D NEONET, starting 2017) moved toward therapeutic applications in oncology and ophthalmology. This suggests a gradual progression from materials development toward drug delivery and disease-specific applications, though the small sample size limits any strong conclusion.

Blafar appears to be moving from foundational biomaterials work toward applied drug delivery, particularly in oncology and ophthalmology — suggesting growing interest in therapeutic end-use rather than materials research alone.

How they like to work

Blafar exclusively participates as a partner, never leading projects, which is typical for a small industry player embedded in academic training networks. With 34 unique consortium partners across 10 countries from just 3 projects, they operate within large, diverse MSCA consortia. This suggests they are an accessible, low-friction industry partner valued for hosting researchers and providing real-world application context rather than driving research agendas.

Despite only three projects, Blafar has built connections with 34 partners across 10 countries, reflecting the large consortium sizes typical of MSCA networks. Their network is broad but shallow — wide geographic reach through structured training programmes rather than deep bilateral relationships.

What sets them apart

Blafar occupies a niche as an Irish SME that bridges biomaterials science and pharmaceutical applications, making it a useful industry node in academic training networks. Their involvement across antibacterial polymers, tissue engineering tools, and drug delivery gives them cross-disciplinary versatility uncommon for a company of their size. For consortium builders, they offer an accessible industry partner in Ireland with hands-on experience hosting early-career researchers in a commercial biomedical setting.

Highlights from their portfolio

• MATRIXASSAY
  Largest funded project (EUR 40,500), developing a commercially relevant cell migration assay platform based on microtissue technology.
• 3D NEONET
  Most recent and longest-running project (2017–2022), addressing drug delivery for both oncology and eye therapeutics — indicating therapeutic ambition beyond materials research.